BioSpace News Archive

ResMed announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. at the Westin St. Francis in San Francisco, CA.

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 1:30 PM PT in San Francisco, California.

CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024.

Elpiscience Biopharma, Ltd. and Astellas Pharma Inc. announced a research collaboration and license agreement for novel bi-specific macrophage engagers, ES019 and another program.

Diversified biotechnology company CCM Biosciences announced the launch of its business unit CCM 5Prime Sciences focused on the development and application of proprietary technology in the domain of DNA biotechnology.

Kuros Biosciences, a leader in next generation bone graft technologies, announced results from two prospective, randomized clinical studies - the STRUCTURE and MAXA trials.

Opthea Limited announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.

Annexon, Inc. announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the appointment of Gunnar Olsson as CEO has been extended.

Matinas BioPharma Holdings, Inc. announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFα and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases.